Abstract
In nine patients with hemolytic-uremic syndrome, the plasma activity and plasma concentrations of antithrombin III were determined on admission to the hospital and during the clinical course of the disease. Hemodialysis was necessary in six of the patients. In seven children the plasma AT III activity was moderately to markedly below the lower limit of normal at 75%, and did not rise after plasmapheresis with fresh frozen plasma. Replacement therapy with AT III concentrate was started in these patients. During the first 2 days an average dose of AT III concentrate of 2.1 U/kg in 24 h was necessary to raise plasma AT III activity by 1%. No side effects were observed. An already pre-existing procoagulant status and the administration of heparin may lead to AT III deficiency in hemolyticuremic syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Avalos JS, Vitacco M, Molinas F, Penalver J, Gianantonio C (1970) Coagulation studies in the hemolytic-uremic syndrome. J Pediatr 76:538–548
Baele G, Matthys E, De Cock G, Thievy M, Barbier F (1977) Antithrombin III activity measured with a chromogenic substrate, in patients with hepatic cirrhosis, with prosthetic heart valves and during parenteral administration of medroxyprogesterone acetate as a contraceptive agent. Thromb Haemost 38:308
Beattie BJ, Murphy AV, Willoughby MLN, Machin SJ, Defreyn G (1981) Plasmapheresis in hemolytic-uremic syndrome of children. Br Med J 282:1667
Bick RL, Bick MD, Fekete LF (1980) Antithrombine III patterns in disseminated intravascular coagulation. Am J Clin Pathol 73:577–583
Brandt P, Jespersen J, Gregersen G (1980) Postpartum hemolyticuremic syndrome successfully treated with antithrombin III. Br Med J 1:449
Brandt P, Jespersen J, Gregersen G (1981) Postpartum hemolyticuremic syndrome treated with antithrombin III. Nephron 27: 15–18
Chan TK, Chan V (1981) Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells. Thromb Haemost 46:504–506
Chester AC, Preuss HG (1982) Postpartum hemolytic-uremic syndrome. Nephron 32:95
de Chadarévian JP, Kaplan BS (1978) The hemolytic-uremic syndrome of childhood. In: Rosenberg HS, Bolande RP (eds) Perspect Pediatr Pathol 4:465–502
Duckert F (1973) Behaviour of antithrombin III in liver disease. Preliminary results. Scand J Gastroenterol 8:109–111
Fong JSC, de Chadarévian JP, Kaplan BS (1982) Hemolyticuremic-syndrome. Current concepts and management. Pediatr Clin North Am 29:835–856
Gervais M, Richardson JB, Chin J, Drummond KN (1971) Immunofluorescent and histologic findings in the hemolytic-uremic syndrome. Pediatrics 2:352–359
Gilchrist GS, Lieberman E, Ekert H, Fine RN, Grishkin C (1969) Heparin therapy in the hemolytic-uremic syndrome. Lancet i: 1123–1126
Gillor A, Bulla M, Bussmann K, Schrör K, Tekook A (1981) Plasma exchange as a therapeutic measure in hemolytic-uremic syndrome in children. In: Bulla M (ed) Renal insufficiency in children. Springer Verlag, Berlin Heidelberg New York, pp 179–183
Gillor A, Bulla M, Roth B, Bussmann K, Schrör K, Tekook A (1983) Plasmapheresis as a therapeutic measure in hemolyticuremic syndrome in children. Klin Wochenschr 61:363–367
Katz J, Lurie A, Kaplan BS, Krawitz S, Metz J (1971) Coagulation findings in the hemolytic-uremic syndrome of infancy; similarity to hyperacute renal allograft rejection. J Pediatr 78: 426–434
Kisker CT, Rush RA (1975) Absence of intravascular coagulation in the hemolytic-uremic syndrome. Am J Dis Child 129:223–226
Klein PJ, Bulla M, Newman RA, Müller P, Uhlenbruck G, Schäfer HE, Fisher R, Krüger G (1977) Thomson-Friedenreich antigen in hemolytic-uremic-syndrome. Lancet 2:1024
Lieberman E (1972) Hemolytic-uremic syndrome. J Pediatr 80: 1–16
Marciniak E, Gockermann JP (1977) Heparin induced decrease in circulating antithrombin III. Lancet ii:581–584
Marciniak E, Kamut R, Brennan LV (1983) Intravascular and extravascular forms of inactive antithrombin III. Thromb Haemost 50:101
Monnens L, de Jong M, van Oostrom C, van Munster P (1982) Antithrombin III levels in children with the epidemic form of hemolytic-uremic syndrome. Nephron 2:261–262
Rao AK, Schneider B, Beckett C, Willis J, Block J, Brown LW, Grover W, Schleman M, Walsh PN (1982) The hemostatic system in children undergoing intensive plasma exchange. J Pediatr 100:69–75
Remuzzi G, Marchesi D, Mecca G, Misiani R, Livio M, De Gaetano G, Donati MB (1978) Hemolytic-uremic syndrome: Deficiency of plasma factor(s) regulating prostacyclin activity. Lancet 2:871–872
Sas G, Blasko G, Banhegyi D, Jako J, Palos LA (1974) Abnormal antithrombin III as a cause of familial thrombophilia. Thromb Diat Haemorrh 32:105–115
Sas G, Köves A, Petö I (1977) Detection of antithrombin III (AT III) complexes in “hypercoagulable” and hyperfibrinolytic states. Thromb Haemost 38:164
Schrader J, Köstering H, Zückner C, Kaiser H, Kramer P, Scheler F (1981) Antithrombin III-Bestimmung im Schnelltest: Ein Vergleich mit Partigen-Platten und einem chromogenen Substrat. Lab Med 5:211–218
Sultan Y, Bussel H, Maisonneuve P, Poupeney M, Sitty X, Gajdos P (1979) Potential danger of thrombosis after plasmaexchange in the treatment of patients with immune disease. Transfusion 19:588–593
Thaler E, Lechner K (1981) Antithrombin III deficiency and thromboembolism. Clin Haematol 10:369–390
Thaler E, Balzar P, Rospa H, Pingerra WF (1978) Acquired antithrombin III deficiency in patients with glomerular proteinuria. Haemostasis 7:257–272
Turney JH, Woods HF, Weston MJ (1979) Regular haemodialysis therapy (RDT) induces a prothrombotic state. Thromb Haemost 42:67
Turney JH, Fewell M, Williams LC, Dodd N, Weston MJ (1982) Paradoxical behaviour of antithrombin III during hemodialysis and its prevention with prostacyclin. Clin Nephrol 1:31–35
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roth, B., von Lilien, T., Busch, B. et al. Deficiency of antithrombin III in children with hemolytic-uremic syndrome. Eur J Pediatr 142, 16–20 (1984). https://doi.org/10.1007/BF00442583
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00442583